Goetzl et al. reported significantly lower NDE levels of synaptophysin, synaptopodin, synaptotagmin-2, neurogranin (NRGN), and growth-associated protein 43 (GAP43) in AD patients compared to controls. This evidence concerns the gene GAP43 and Alzheimer disease.